Frontiers in Medical Science Research, 2025, 7(2); doi: 10.25236/FMSR.2025.070206.
Bixiu Zhai1, Xuli Chen1, Jiajia Liu2
1The Second Affiliated Hospital of Wannan Medical College, Department of Electrocardiogram Function, Wuhu, Anhui, China
2Department of Cardiovascular Medicine, the Second Affiliated Hospital of Wannan Medical College, Wuhu, China
Acute myocardial infarction (AMI), a life-threatening cardiovascular emergency, necessitates prompt diagnosis to optimize therapeutic outcomes. This prospective cohort study evaluated the diagnostic efficacy of serum heart-type fatty acid-binding protein (H-FABP), cardiac troponin I (cTnI), and electrocardiography (ECG) in 240 patients presenting with chest pain (150 AMI, 90 non-AMI) alongside 240 healthy controls. Coronary angiography served as the diagnostic gold standard. Serum biomarkers were quantified using immunoturbidimetric (H-FABP) and chemiluminescent (cTnI) assays, while ECG abnormalities were assessed per standardized criteria.Key findings revealed significantly elevated H-FABP and cTnI levels in AMI patients compared to non-AMI and control groups (P < 0.05), with concentrations correlating positively with coronary lesion severity (Gensini score: moderate-severe vs. mild group, P < 0.05). ECG demonstrated 82.7% sensitivity but limited specificity (46.7%) for AMI detection. ROC analysis identified optimal diagnostic thresholds at 8.78 μg/L (H-FABP, AUC=0.781) and 0.65 ng/mL (cTnI, AUC=0.912), while combined biomarker-ECG assessment achieved superior diagnostic accuracy (AUC=0.966, 95% CI: 0.934–0.986), significantly outperforming individual modalities (P < 0.05). These results underscore the complementary role of H-FABP (providing early ischemic signals) and cTnI (confirming myocardial injury) in AMI diagnosis. Multimodal integration with ECG enhances diagnostic precision during the critical therapeutic window, facilitating timely intervention to mitigate infarct expansion. This strategy addresses the limitations of isolated ECG interpretation and delayed cTnI elevation, offering a clinically actionable approach for rapid AMI triage.
acute myocardial infarction, heart-type fatty acid-binding protein, cardiac troponin I, electrocardiography
Bixiu Zhai, Xuli Chen, Jiajia Liu. Biomarker-Electrocardiography Synergy: Evaluating H-FABP and cTnI Serum Levels with ECG for Acute Myocardial Infarction Diagnosis. Frontiers in Medical Science Research(2025), Vol. 7, Issue 2: 29-34. https://doi.org/10.25236/FMSR.2025.070206.
[1] Zhang L, Desai NR, Li J, et al. National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. J Am Heart Assoc. 2015, 4(7): e001906. doi: 10.1161/JAHA.115.001906.
[2] Neumann JT, Sörensen NA, Ojeda F, et al. Immediate Rule-Out of Acute Myocardial Infarction Using Electrocardiogram and Baseline High-Sensitivity Troponin I. Clin Chem. 2017, 63(1): 394-402. doi: 10.1373/clinchem.2016.262659.
[3] Xu LQ, Yang YM, Tong H, et al. Early Diagnostic Performance of Heart-Type Fatty Acid Binding Protein in Suspected Acute Myocardial Infarction: Evidence From a Meta-Analysis of Contemporary Studies. Heart Lung Circ. 2018, 27(4): 503-512. doi: 10.1016/j.hlc.2017.03.165.
[4] Eggers KM, Hammarsten O, Lindahl B, et al.. Differences between high-sensitivity cardiac troponin T and I in stable populations: underlying causes and clinical implications. Clin Chem Lab Med. 2022, 61(3): 380-387. doi: 10.1515/cclm-2022-0778.
[5] Otaki Y, Watanabe T, Kubota I, et al.. Heart-type fatty acid-binding protein in cardiovascular disease: A systemic review. Clin Chim Acta. 2017, 474: 44-53. doi: 10.1016/j.cca.2017.09.007.
[6] Sotoudeh Anvari M, Karimi M, et al. Complementary Diagnostic Value of Heart Type Fatty Acid-binding Protein in Early Detection of Acute Myocardial Infarction. Crit Pathw Cardiol. 2018, 17(1): 43-46. doi: 10.1097/HPC.0000000000000107.
[7] Rexhaj E, Bär S, Soria R, et al. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy. Atherosclerosis. 2024, 392: 117504. doi: 10.1016/j.atherosclerosis.2024.117504.
[8] Ye XD, He Y, Wang S, et al. Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis. Ann Med. 2020, 52(8): 444-461. doi: 10.1080/07853890.2020.1800075.
[9] Wu S, Zou S, Wang S, et al. CTnI diagnosis in myocardial infarction using G-quadruplex selective Ir() complex as effective electrochemiluminescence probe. Talanta. 2022, 248: 123622. doi: 10.1016/j.talanta.2022.123622.
[10] Bivona G, Agnello L, Bellia C, et al. Diagnostic and prognostic value of H-FABP in acute coronary syndrome: Still evidence to bring. Clin Biochem. 2018, 58: 1-4. doi: 10.1016/j.clinbiochem.2018.04.021.
[11] Miao Y, Liu Y, Liu C, et al. Diagnostic Value of Echocardiography Combined with Serum h-FABP and cTnI in Myocardial Infarction and Its Evaluation Value in Left Ventricular Function. Evid Based Complement Alternat Med. 2022, 2022: 8809708. doi: 10.1155/2022/8809708.